The fifth surfactant to be approved to treat Respiratory Distress Syndrome

(RDS) was approved by the FDA today. the new drug is called Surfaxin (lucinactant) and joins the 4 previously approved medicines for RDS. This drug was approved to prevent RDS based on one study of 1,294 premature infants. read the release at www.fda.gov.

Information on this site reflects current information on medicines and is NOT medical advice. Talk to your doctor BEFORE making any changes, additions or deletions of any therapy. As noted in every previous edition of the Essential Guide to Prescription Drugs and the Essential Guide to Medical News, no claim is made that ALL known actions, uses, side effects, adverse effects, precautions or interactions for a drug are included in the information provided. While diligent care has been taken to ensure the accuracy of the information provided, the continued accuracy and currentness are ever subject to change